Table 4.
Variables associated with overall survival among 284 patients
|
Co-variable |
No. |
Univariate analysis |
Multivariate analysis |
||||
|---|---|---|---|---|---|---|---|
| MST (months) | P | Variate | OR | 95% CI | P | ||
| Age |
|
|
|
|
|
|
|
| < 70 |
231 |
22.8 |
|
|
|
|
|
| > 70 |
53 |
24.3 |
0.625 |
|
|
|
|
| Gender |
|
|
|
|
|
|
|
| Male |
168 |
20.1 |
|
|
|
|
|
| Female |
116 |
32.4 |
0.0086 |
Female |
1.06 |
0.75-1.58 |
0.75 |
| Smoking status |
|
|
|
|
|
|
|
| Yes |
174 |
20.1 |
|
|
|
|
|
| No |
110 |
33.4 |
0.0012 |
No smoking status |
0.84 |
0.52-1.24 |
0.39 |
| ECOG PS |
|
|
|
|
|
|
|
| 0-1 |
238 |
29.5 |
|
|
|
|
|
| >2 |
46 |
7.9 |
<.0001 |
PS 0-1 |
0.34 |
0.24-0.50 |
<.0001 |
| Stage |
|
|
|
|
|
|
|
| IIIB |
25 |
30.2 |
|
|
|
|
|
| IV |
259 |
22.5 |
0.269 |
|
|
|
|
| EGFR mutation |
|
|
|
|
|
|
|
| Mt (+) |
121 |
39.2 |
|
|
|
|
|
| Mt (−) |
163 |
17.8 |
<.0001 |
Mutant EGFR |
0.53 |
0.34-0.84 |
0.0069 |
| PCV |
|
|
|
|
|
|
|
| < 2.2 ng/ml |
150 |
38.6 |
|
|
|
|
|
| ≥ 2.2 ng/ml |
134 |
15.0 |
<.0001 |
< 2.2 ng/ml |
0.43 |
0.31-0.59 |
<.0001 |
| CEA |
|
|
|
|
|
|
|
| < 5.0 ng/ml |
108 |
32.6 |
|
|
|
|
|
| ≥ 5.0 ng/ml |
176 |
21.0 |
0.036 |
< 5.0 ng/ml |
0.93 |
0.67-1.26 |
0.63 |
| Start dates of IT |
|
|
|
|
|
|
|
| Before 1/ 4/ 2008 |
79 |
34.1 |
|
After 1/ 4/ 2008 |
|
|
|
| After 1/ 4/ 2008 |
205 |
19.3 |
0.0030 |
|
0.73 |
0.50-1.15 |
0.07 |
| EGFR-TKI treatment |
|
|
|
|
|
|
|
| Yes |
143 |
33.7 |
|
|
|
|
|
| No | 141 | 15.3 | <.0001 | Yes | 0.76 | 0.50-1.15 | 0.20 |
IT: initial therapy, PCV: pretreatment CYFRA 21–1 value, Mt(+): mutant EGFR, M(−): wild-type EGFR.